Home Clinical trials For patients Ovary DS3939-077

DS3939-077

Phase 1/2, Open-Label, Multicenter, First-In-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

On hold
Trial drug
DS3939a
Grade
High grade, Low grade, Other / unknown
Prior lines
1, 2, 3, 4, >4
Histology
Serous, Endometrioid Mucinous Clear-cell Other (bv. mixed/rare)
Platin
Platinum resistant
Secondary platinum refractory
Primary platinum refractory
Phase
I

Treatment

The treatment option in this study is DS3939a.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.